Study the effect of mifepristone on clinical symptoms and its side effects in patients with fibroid uterus
Keywords:Clinical symptoms, Fibroid, Mifepristone
Background: Fibroid can lead to a variety of clinical symptoms including pain, menorrhagia, and lump in abdomen. The availability of a safe and efficient medical management options for symptomatic fibroid is of considerable clinical and public health importance. The present study is designed to see the safety and efficacy of mifepristone in the medical management of uterine fibroids.
Methods: The study was conducted in the Department of Obstetrics and Gynaecology, Himalayan Institute of Medical Sciences, Swami Ram Nagar, Dehradun over a period of 12 months. A total of 40 patients were included in the study.
Results: Amount of bleeding was assessed by PBAC score, which significantly reduced by 83.9% at the end of treatment. And 62% patients developed amenorrhoea due to mifepristone. Similarly, pain abdomen/dysmenorrhoea was assessed by Numeric Pain Rating Scale, which also showed a significant reduction in 55% patients with no pain at the end of 3 months.
Conclusions: The study clearly shows that Mifepristone is a safe and effective option to manage fibroid uterus and its associated symptoms.
Kulshrestha V, Kriplani A, Agarwal N, Sareen N, Garg P, Hari S, et al. Low dose mifepristone in medical management of uterine leiomyoma - an experience from a tertiary care hospital from north India. Indian J Med Res. 2013;137(6):1154–62.
Tropeano G, Amoroso S, Scambia G, Levy BS. Management of Uterine Fibroids. Hum Reprod Update. 2007;14(3):812-23.
Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contracep. 2010; 82(5):442-52.
Cadepond, PhD F, Ulmann, MD, PhD A, Baulieu, MD, PhD EE. RU486 (mifepristone): mechanisms of action and clinical uses. Ann Review Med. 1997;48(1):129-56.
Narvekar N, Critchley HO, Cheng L, Baird DT. Mifepristone induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod. 2006;21(9): 2312-8.
Seth S, Goel N, Singh E, Mathur AS, Gupta G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J Midlife Health. 2013;4(1):22-6.
Sinha M, Kyal A, Mukhopadhay P. Effectiveness of Mifepristone in the Treatment of Uterine Leiomyomata. Nepal J Obstet Gynaecol. 2013 ;8(1):22-5.
Das SS. Prospective Study on Low-Dose Mifepristone for the Treatment of Leiomyoma: A Hospital Based Study. Int Arch BioMed Clinic Res. 2018 21;4(1):104-6.
Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra ow-dose mifepristone for the treatment of uterine leiomyomata. European J Obstet Gynecol Reproduct Biol. 2009;146(2):215-8.
Arora D, Chawla J, Kochar SP, Sharma JC. A randomized control trial to assess efficacy of Mifepristone in medical management of uterine fibroid. Med J Armed Forces India. 2017;73(3):267-73.
Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol. 2006;108(6):1381-7.
Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust NZJ Obstet Gynaecol. 2009;49(1):77-83.
Sudha B, Kumari D. effect of low dose mifepristone in symptomatic uterine leiomyoma. J Evidence Med Healthcare. 2016;3(21):909-13.